CanSino Biologics Inc. (688185.SS)
CNY 63.42
(0.21%)
CNY 63.42
(0.21%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -857.83 Million | -1.88 Billion | 2.01 Billion | -469.38 Million | -170.18 Million | -123.63 Million |
| Net Income | -1.48 Billion | -1.18 Billion | 1.9 Billion | -407.04 Million | -156.76 Million | -138.28 Million |
| Depreciation & Amortization | 269.05 Million | 196.36 Million | 88.54 Million | 31.81 Million | 22.47 Million | 12.01 Million |
| Deferred income taxes | -11.45 Million | -196.96 Million | -43.58 Million | -7.79 Million | -128 Thousand | -12.33 Million |
| Stock-based compensation | 9.54 Million | 10.08 Million | 9.8 Million | 17.51 Million | 21.51 Million | 15.78 Million |
| Change in working capital | -179.4 Million | -1.47 Billion | 84.3 Million | -100.77 Million | -12.81 Million | 378 Thousand |
| Other non-cash items | 1.14 Billion | 765.88 Million | -31.59 Million | -3.1 Million | -44.47 Million | -1.19 Million |
| Investing Cash Flow | -511.24 Million | -1.19 Billion | -2.53 Billion | -182.71 Million | -797.77 Million | 117.62 Million |
| Investments in PPE | -610.47 Million | -1.07 Billion | -1.2 Billion | -270.77 Million | -116.94 Million | -160.67 Million |
| Acquisitions | -24.62 Thousand | -3.25 Million | -64.87 Million | -886 Thousand | -6.89 Million | 11.25 Million |
| Investment purchases | -8.2 Billion | -12.36 Billion | -8.47 Billion | -6.28 Billion | -1.66 Billion | -1.44 Billion |
| Sales/Maturities of investments | 8.3 Billion | 12.21 Billion | 7.12 Billion | 6.25 Billion | 967.86 Million | 1.72 Billion |
| Other Investing Activities | 8.02 Million | 35.68 Million | 94.02 Million | 120.34 Million | 22.85 Million | -9.28 Million |
| Financing Cash Flow | -7.58 Million | 854.6 Million | 1.55 Billion | 4.94 Billion | 1.09 Billion | 45.05 Million |
| Debt repayment | -86.26 Million | -1.36 Billion | -160 Million | -22.49 Million | -7.3 Million | -41.66 Million |
| Dividends payments | -3.62 Million | -193.93 Million | -14.09 Million | -6.69 Million | -8.78 Million | -7.59 Million |
| Common Stock Repurchased | - | -150.16 Million | - | - | - | - |
| Common Stock Issuance | - | - | - | -13.55 Million | 1.12 Billion | 17.48 Million |
| Other Financing Activities | -73.74 Million | 2.56 Billion | 1.73 Billion | 4.97 Billion | -28.16 Million | 35.16 Million |
| Accounts receivables | 265.96 Million | -495.79 Million | -419.93 Million | -107.75 Million | -8.59 Million | -7.95 Million |
| Accounts payables | -108.3 Million | -683.81 Million | 1.21 Billion | 155.57 Million | 8.59 Million | - |
| Inventory | -216.54 Million | -604.01 Million | -706.39 Million | -144.15 Million | -8.08 Million | -6.87 Million |
| Other working capital | -120.52 Million | 304.67 Million | -1.25 Million | -4.43 Million | -4.73 Million | 7.24 Million |
| Cash at beginning of period | 3.39 Billion | 5.45 Billion | 4.44 Billion | 201.97 Million | 57.38 Million | 18.24 Million |
| Cash at end of period | 2.05 Billion | 3.39 Billion | 5.45 Billion | 4.44 Billion | 201.97 Million | 57.38 Million |
| Capital Expenditure | -610.47 Million | -1.07 Billion | -1.2 Billion | -270.77 Million | -116.94 Million | -160.67 Million |
| Effect of forex changes on cash | 20.28 Million | 160.76 Million | -33.78 Million | -27.36 Million | 21.72 Million | 92 Thousand |
| Net cash flow / Change in cash | -1.33 Billion | -2.06 Billion | 1 Billion | 4.24 Billion | 144.59 Million | 39.13 Million |
| Free Cash Flow | -1.46 Billion | -2.96 Billion | 811.42 Million | -740.16 Million | -287.13 Million | -284.31 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 2.96 Million | -55.27 Million | -170.09 Million | -1.48 Billion | -497.7 Million | -143.6 Million |
| Depreciation & Amortization | - | 56.4 Million | 56.4 Million | 269.05 Million | 67.23 Million | 67.23 Million |
| Deferred income taxes | - | - | - | -11.45 Million | -204.63 Million | -227.3 Million |
| Stock-based compensation | - | 2.43 Million | - | 9.54 Million | 9.54 Million | -5.67 Million |
| Change in working capital | - | -12.97 Million | - | -179.4 Million | 60.62 Million | 232.98 Million |
| Other non-cash items | -60.64 Million | 15.23 Million | 104.46 Million | 1.14 Billion | 404.88 Million | 81.29 Million |
| Investing Cash Flow | -661.78 Million | -294.29 Million | 232.44 Million | -511.24 Million | -248.27 Million | -143.77 Million |
| Investments in PPE | -62.98 Million | -128.63 Million | -134.41 Million | -610.47 Million | -163.2 Million | -128.63 Million |
| Acquisitions | 37.5 Thousand | -30.75 Million | - | -24.62 Thousand | 305.14 Thousand | 95.61 Million |
| Investment purchases | -3.94 Billion | -3.43 Billion | -2.14 Billion | -8.2 Billion | -2.93 Billion | -1.57 Billion |
| Sales/Maturities of investments | 3.09 Billion | 3.79 Billion | 1.99 Billion | 8.3 Billion | 1.78 Billion | 2.53 Billion |
| Other Investing Activities | 245.42 Million | -520.92 Million | 520.92 Million | 8.02 Million | 1.13 Billion | -1.07 Billion |
| Financing Cash Flow | -119.59 Million | -260.68 Million | 147.37 Million | -7.58 Million | 123.73 Million | 90.81 Million |
| Debt repayment | -100.84 Million | -240.91 Million | -166.07 Million | -86.26 Million | -145.12 Million | -180.37 Million |
| Dividends payments | - | -16.84 Million | -16.78 Million | -3.62 Million | -33.9 Million | -33.9 Million |
| Common Stock Repurchased | - | - | -16.78 Million | - | 57.89 Million | -57.89 Million |
| Common Stock Issuance | - | - | - | - | - | 35.87 Million |
| Other Financing Activities | -18.75 Million | -14.93 Million | -18.69 Million | -73.74 Million | -31.16 Million | 327.12 Million |
| Accounts receivables | - | 41.37 Million | - | 265.96 Million | 265.96 Million | 171.23 Million |
| Accounts payables | - | - | - | -108.3 Million | - | - |
| Inventory | - | -54.34 Million | - | -216.54 Million | -216.54 Million | 48.15 Million |
| Other working capital | - | - | - | -120.52 Million | 11.2 Million | 13.58 Million |
| Cash at beginning of period | 1.73 Billion | 2.58 Billion | 2.05 Billion | 3.39 Billion | 3.22 Billion | 2.38 Billion |
| Cash at end of period | 1.36 Billion | 1.73 Billion | 2.58 Billion | 2.05 Billion | 2.05 Billion | 2.35 Billion |
| Capital Expenditure | -62.98 Million | -128.63 Million | -134.41 Million | -610.47 Million | -163.2 Million | -128.63 Million |
| Effect of forex changes on cash | - | -2.23 Million | 14.61 Million | 20.28 Million | -31.5 Million | 14.97 Million |
| Net cash flow / Change in cash | -369.72 Million | -848.91 Million | 524.89 Million | -1.33 Billion | -1.16 Billion | -33.05 Million |
| Free Cash Flow | -120.66 Million | -225.07 Million | -200.04 Million | -1.46 Billion | -323.25 Million | -123.7 Million |
TRVN
PGRE
300651
600337
INCAF
6525